Dasatinib Worsens the Effect of Cetuximab in Combination with Fractionated Radiotherapy in FaDu- and A431-derived Xenografted Tumours

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 Aug 1

PMID 25077442

Citations 12

Authors

M Baro

L I de Llobet

A Figueras

I Skvortsova

R Mesia

J Balart

Affiliations

Soon will be listed here.

Abstract

Background: Cetuximab is often combined with radiotherapy in advanced SCCHN. Alternative routes bypassing inhibition of EGFR with cetuximab may overshadow the efficacy of this combination. We undertook this study to investigate a possible role of dasatinib in this scenario.

Methods: The SCC5, SCC25, SCC29, FaDu and A431 cell lines were assessed in vitro for cell proliferation under cetuximab and dasatinib treatments. In FaDu and A431 cells, dasatinib plus cetuximab resulted in higher proliferation than cetuximab alone. Then, FaDu and A431 cells were implanted into subcutaneous tissue of athymic mice that were irradiated with 30 Gy in 10 fractions over 2 weeks, and treated with cetuximab and dasatinib. Tumour growth, DNA synthesis and angiogenesis were determined. The EGFR, RAS-GTP activity, phosphorylated AKT, ERK1/2, SRC protein levels and VEGF secretion were determined in vitro.

Results: The addition of dasatinib to cetuximab and radiotherapy increased tumour growth, DNA synthesis and angiogenesis that were associated with RAS, AKT and ERK1/2 activation, and SRC inhibition in FaDu and A431 cells.

Conclusions: In xenografts derived from these two cell lines, dasatinib did not improve the efficacy of cetuximab combined with radiotherapy. On the contrary, it worsened tumour control achieved by the combination of these two treatments.

Citing Articles

Combinatorial Strategies to Target Molecular and Signaling Pathways to Disarm Cancer Stem Cells.

Catara G, Colanzi A, Spano D Front Oncol. 2021; 11:689131.

PMID: 34381714 PMC: 8352560. DOI: 10.3389/fonc.2021.689131.

Biphasic Mathematical Model of Cell-Drug Interaction That Separates Target-Specific and Off-Target Inhibition and Suggests Potent Targeted Drug Combinations for Multi-Driver Colorectal Cancer Cells.

Shen J, Li L, Yang T, Cohen P, Sun G Cancers (Basel). 2020; 12(2).

PMID: 32069833 PMC: 7072552. DOI: 10.3390/cancers12020436.

The Differential Impact of SRC Expression on the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma.

Hermida-Prado F, Granda-Diaz R, Del-Rio-Ibisate N, Villaronga M, Allonca E, Garmendia I Cancers (Basel). 2019; 11(11).

PMID: 31731442 PMC: 6896085. DOI: 10.3390/cancers11111644.

Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.

Baro M, Lopez Sambrooks C, Burtness B, Lemmon M, Contessa J Mol Cancer Ther. 2019; 18(11):2124-2134.

PMID: 31387891 PMC: 6825559. DOI: 10.1158/1535-7163.MCT-19-0163.

The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042.

Hermida-Prado F, Villaronga M, Granda-Diaz R, Del-Rio-Ibisate N, Santos L, Hermosilla M J Clin Med. 2019; 8(8).

PMID: 31382448 PMC: 6722627. DOI: 10.3390/jcm8081157.

References

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Kehlbach R, Rodemann H . Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654. FEBS Lett. 2010; 584(18):3878-84. DOI: 10.1016/j.febslet.2010.08.005. View

Seoane S, Carlos Montero J, Ocana A, Pandiella A . Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst. 2010; 102(18):1432-46. DOI: 10.1093/jnci/djq315. View

Malumbres M, Barbacid M . RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003; 3(6):459-65. DOI: 10.1038/nrc1097. View

Liang K, Ang K, Milas L, Hunter N, Fan Z . The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 2003; 57(1):246-54. DOI: 10.1016/s0360-3016(03)00511-x. View

Hanke J, Gardner J, Dow R, Changelian P, Brissette W, Weringer E . Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem. 1996; 271(2):695-701. DOI: 10.1074/jbc.271.2.695. View

Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L . Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 2005; 280(35):31182-9. DOI: 10.1074/jbc.M506591200. View

Lin Y, Wu M, Wei T, Chuang S, Chen K, Cheng A . Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells. Neoplasia. 2012; 14(6):463-75. PMC: 3394189. DOI: 10.1596/neo.12300. View

Wu Z, Doondeea J, Gholami A, Janning M, Lemeer S, Kramer K . Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics. 2011; 10(12):M111.011635. PMC: 3237086. DOI: 10.1074/mcp.M111.011635. View

10.

Lombardo L, Lee F, Chen P, Norris D, Barrish J, Behnia K . Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47(27):6658-61. DOI: 10.1021/jm049486a. View

11.

Erjala K, Sundvall M, Junttila T, Zhang N, Savisalo M, Mali P . Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2006; 12(13):4103-11. DOI: 10.1158/1078-0432.CCR-05-2404. View

12.

Hunter T . Oncoprotein networks. Cell. 1997; 88(3):333-46. DOI: 10.1016/s0092-8674(00)81872-3. View

13.

Roskoski Jr R . Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun. 2004; 324(4):1155-64. DOI: 10.1016/j.bbrc.2004.09.171. View

14.

Luo F, Barrett Y, Yang Z, Camuso A, McGlinchey K, Wen M . Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol. 2008; 62(6):1065-74. DOI: 10.1007/s00280-008-0699-5. View

15.

Summy J, Gallick G . Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res. 2006; 12(5):1398-401. DOI: 10.1158/1078-0432.CCR-05-2692. View

16.

Li C, Iida M, Dunn E, Ghia A, Wheeler D . Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009; 28(43):3801-13. PMC: 2900381. DOI: 10.1038/onc.2009.234. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Giannoni E, Buricchi F, Raugei G, Ramponi G, Chiarugi P . Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol. 2005; 25(15):6391-403. PMC: 1190365. DOI: 10.1128/MCB.25.15.6391-6403.2005. View

19.

Koppikar P, Choi S, Egloff A, Cai Q, Suzuki S, Freilino M . Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res. 2008; 14(13):4284-91. PMC: 3428119. DOI: 10.1158/1078-0432.CCR-07-5226. View

20.

Pueyo G, Mesia R, Figueras A, Lozano A, Baro M, Vazquez S . Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy. Oncologist. 2010; 15(9):976-86. PMC: 3228040. DOI: 10.1634/theoncologist.2008-0290. View